PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Chunhua Ma

Nankai University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 19, 2026 · JOURNAL ARTICLE

Genetic Engineering of Tumor‐Infiltrating Lymphocytes ( TIL ) via a T‐Editor Platform to Enhance Anti‐Tumor Activity

Cancer Science

Early-stage mechanistic work demonstrating proof-of-concept for a gene-editing platform in preclinical and PDX models, without human clinical efficacy data or direct comparison to standard TIL therapy.

PreliminaryYongming Xue Xuejiao Ma CAR-T Cell Therapy Research

Study details

DesignPreclinical proof-of-concept and patient-de…

InterventionT-Editor platform with cytosine base editin…

ComparatorNon-engineered control TIL and Cas9-knockou…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support